Rablet-D

Quick links to important sections

Rablet-D

Method of action: Antiulcer, Laxative

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rablet-D

What is Rablet-D?

Rablet-D is a prescription medication that combines two different pharmacological agents: Rabeprazole and Domperidone. This combination is primarily used to manage conditions where excess stomach acid production is complicated by issues with gastric motility or nausea.

Components of Rablet-D

The effectiveness of Rablet-D is derived from the interaction of its two active ingredients:

  • Rabeprazole: This component belongs to a class of drugs known as proton pump inhibitors (PPIs). It works by targeting the acid-producing pumps in the stomach lining, effectively reducing the total amount of acid secreted into the digestive system.
  • Domperidone: This component is classified as a prokinetic and an anti-dopaminergic agent. It helps facilitate the movement of food through the digestive tract and prevents the backward flow of stomach contents into the esophagus. It also acts on the signals in the brain that trigger the sensation of nausea.

Mechanism of Action

Rablet-D functions through a dual approach. While the Rabeprazole component lowers the acidity levels to prevent irritation of the gastrointestinal lining, the Domperidone component ensures that the stomach empties more efficiently. By improving the coordination of the digestive muscles and reducing acid volume, the medication helps address the underlying physiological factors associated with acid reflux and functional dyspepsia.

What side effects are possible with Rablet-D?

Possible Side Effects and Safety Information

The official safety profile for the Rabeprazole and Domperidone combination is organized by regulatory documents into specific categories of adverse reactions and safety constraints. Adverse effects are classified by frequency and System-Organ-Class (SOC) to provide a structured overview of potential risks.


Frequency-Classified and Systemic Adverse Reactions

The most frequently reported effects, generally classified as Common, include headache, diarrhea, nausea, abdominal pain, and flatulence. Reactions falling into the Uncommon category may involve dizziness, somnolence, and nervousness. Adverse reactions are grouped by the affected body system, featuring effects on Gastrointestinal Disorders, Nervous System Disorders, Endocrine Disorders (related to increased prolactin levels), and Cardiac Disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights the potential for rare but serious events. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS), associated with Rabeprazole. The Domperidone component carries the risk of serious ventricular arrhythmias, including QT prolongation and Torsades de Pointes.

Duration-related safety patterns are noted, such as the increased risk of bone fracture and Hypomagnesemia (low magnesium levels) associated with long-term use (e.g., typically a year or more). Use is contraindicated in specific patient groups, particularly those with existing moderate or severe hepatic impairment, known cardiac conduction issues, or certain gastrointestinal conditions (e.g., hemorrhage or obstruction). The cardiac risk related to Domperidone is considered higher in older adults (over 60 years).

Overdose and Emergency Response

Overdose and When to Seek Help

If an overdose of Rablet-D is suspected, individuals must seek medical attention straight away. Regulatory documents mandate that standard symptomatic treatment should be given immediately under close medical supervision.

Documented Manifestations and Risks

The official overdose profile highlights that effects related to the Rabeprazole component are generally minimal and reversible. However, manifestations associated with the Domperidone component have been reported, primarily in infants and children, and may include agitation, altered consciousness, disorientation, somnolence, convulsion, and extrapyramidal reactions.

Due to the possibility of QT prolongation linked to the prokinetic component, ECG monitoring should be undertaken in an overdose situation. Treatment focuses on supportive care, as no specific antidote is known for either active ingredient.

Supportive Measures

Management is restricted to symptomatic and general supportive measures. Procedural steps, such as gastric lavage and administration of activated charcoal, may be utilized for supportive management. It is noted that the Rabeprazole component is not dialysable due to its extensive protein binding.

Therapeutic Uses of Rablet-D

What Rablet-D Treats: Main Uses and Benefits

The combination is used to help manage two main groups of symptoms related to upper gastrointestinal distress: symptoms related to excessive acidity and symptoms related to impaired digestive movement.


Targeted Symptomatic Relief for Complex Digestive Conditions

This combination is generally used for conditions characterized by periods of heightened symptoms, such as Gastroesophageal Reflux Disease (GERD) and peptic ulcers (sores in the stomach or duodenum). It is commonly applied in settings where additional management of discomfort is required. Clinical indications include symptomatic erosive esophagitis, active duodenal ulcer, and use in situations involving recurrent or episodic manifestations of GORD. The treatment provides support that helps ease the overall burden of symptoms related to physical discomfort.

It is particularly relevant for managing symptoms related to organ-specific functional stress. This includes manifestations like pronounced nausea, vomiting, upper abdominal bloating, and the feeling of fullness shortly after eating. It helps address groups of symptoms that may interfere with daily stability.

“The medication may assist with managing multiple symptoms that appear suddenly or fluctuate.”

The therapy contributes to improved day-to-day comfort during symptomatic periods, assisting with maintaining functional stability.


Quick Fact: Support for Complex Symptom Patterns The medication is considered relevant for patients whose upper gastrointestinal discomfort is related to both excessive acidity and physical functional stress.

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility profile for Rablet-D (a combination of rabeprazole and domperidone) is strictly defined by regulatory health authorities based on absolute prohibitions and population-specific restrictions.

Category Eligibility Rule (Official Statement)
Absolute Contraindications Use is prohibited for patients with a known hypersensitivity to the ingredients, a prolactin-releasing pituitary tumor (prolactinoma), or moderate to severe hepatic impairment (liver failure).
Cardiac Status The medicine must not be used in patients with a history of QT-interval prolongation, pre-existing cardiac diseases (like congestive heart failure), or significant electrolyte disturbances (e.g., hypokalemia).
Gastrointestinal Risk It is contraindicated if stimulating gastrointestinal motility could be harmful, such as in cases of gastro-intestinal hemorrhage, mechanical obstruction, or perforation.
Age Groups The combination is not recommended for use in children and adolescents (under 18 years) due to insufficient safety and efficacy data. Older adults require caution and may be restricted based on cardiac risk factors.
Pregnancy/Lactation Use is contraindicated during pregnancy and must not be used during breastfeeding.

Eligibility is limited to adults who do not have any of the absolute contraindications and who require conditional use, such as those with mild to moderate renal impairment, where caution and monitoring are necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents establish several pharmacokinetic and pharmacodynamic restrictions for the Rabeprazole-Domperidone combination, requiring the avoidance or prohibition of specific co-administered substances. The interaction profile is defined by the gastric acid suppression of the Rabeprazole component and the metabolic and cardiac risks of the Domperidone component.


Official Interaction Statements

Classification Interacting Substance/Class Regulatory Basis of Restriction
Contraindicated Potent CYP3A4 Inhibitors (e.g., Clarithromycin) Increased Domperidone plasma exposure, elevating the risk of QT interval prolongation.
Contraindicated Rilpivirine (Antiretroviral) Rabeprazole-induced pH elevation significantly reduces Rilpivirine absorption, risking therapeutic failure.
Exposure Risk pH-Dependent Drugs (e.g., Ketoconazole, Iron Salts) Rabeprazole decreases the absorption and systemic availability of drugs that require acidic gastric pH.
Pharmacodynamic QT-prolonging Drugs Additive pharmacodynamic effect on cardiac repolarization, increasing the risk of arrhythmia.

Population-Specific and Other Notes

Co-administration with Methotrexate may increase its serum concentration. Increases in the International Normalized Ratio (, INR) have been reported with concomitant Warfarin use. For individuals with Severe Renal Impairment, Domperidone's elimination half-life is officially documented as prolonged, increasing systemic exposure and associated risks. A high-fat meal may delay the time to maximum concentration (, Tmax) of Rabeprazole, but the total extent of absorption is not altered.

Mechanism of Action

Mechanism of Action: How Rablet-D Works

Rabeprazole acts by selectively accumulating in the acidic secretory canaliculi of the gastric parietal cells, where it is converted into its active metabolite. This metabolite then covalently and irreversibly binds to and inhibits the gastric Proton Pump ( H^+/ K^+-ATPase) , blocking the final transport step of hydrogen ions. This results in an extended reduction in the hydrogen ion concentration of the stomach contents.

Simultaneously, domperidone acts as an antagonist of peripheral Dopamine D2 receptors in the upper gastrointestinal tract and the Chemoreceptor Trigger Zone (CTZ) . In the gut wall, this antagonism enhances acetylcholine action, leading to increased lower esophageal sphincter (LES) tone and a modified rate of gastric content transit. In the CTZ, the blockage of D2 receptors alters the sequence of events leading to the emesis reflex.

Dosage and Administration Information

How to Use Rablet-D

This section describes the administration rules and dosing protocols established for Rablet-D (Rabeprazole/Domperidone FDC).


Administration Scope

Entity Official Administration Guideline
Route of administration The medicine is strictly for oral administration.
Dosing schedule (Adult) The standard regimen is one capsule once daily (Rabeprazole 20 mg / Domperidone 30 mg SR). Dosing may be extended to up to two times a day depending on the prescribed regimen.
Timing in relation to meals The capsule is typically directed to be taken before meals.
Age-group rules The FDC is not recommended for use in children due to a lack of established data for this population.
Missed-dose rules If a dose is missed, it must be omitted, and the standard schedule should be resumed; the dose must not be doubled.

Administration Requirements and Duration

Preparation and Integrity: The capsule must be swallowed whole with an appropriate amount of liquid. It is an explicit condition that the medicine must not be chewed, crushed, or split to maintain the integrity of its specialized enteric coating and sustained-release (SR) formulation.

Course Duration: The use of the Rabeprazole component for healing acute conditions is typically a short-term course of 4 to 8 weeks. For certain conditions, maintenance use may be extended for up to 12 months, based on the prescribed regimen.

Population Adjustments: For repeated administration in patients with severe renal impairment, the dosing frequency of the Domperidone component may need to be reduced as directed.

These directives establish the procedural structure for the medicine's usage, defining the method of intake, timing, frequency, and maximum duration defined in product specifications.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Core Mechanism and Target

Research has evaluated the compound's effect on specific inflammatory pathways (e.g., the COX-2 enzyme) relevant to acid-related conditions. Studies have investigated this in cellular models to analyze the compound's effect on indicators of immune response.


Clinical Efficacy and Outcomes

Studies have investigated the measurement of joint function and pain levels in individuals with chronic inflammatory conditions. Researchers have primarily focused on randomized controlled trials (RCTs) comparing the compound to a placebo or an active comparator.

  • Pain Levels: Data from short-term trials (1-3 months) were compiled to evaluate the change in pain scores.
  • Joint Function: Measurements such as the WOMAC index were used to track physical function.
  • Long-Term Impact: Researchers have explored the long-term impact on inflammation, primarily by monitoring blood markers like C-reactive protein (CRP) over periods up to one year. Studies have examined the role of the drug for long-term management.

Safety and Side Effects

Reported data describes the side effect profile for most individuals included in clinical trials. Common side effects reported included gastrointestinal upset and headaches.

  • Cardiovascular Health: Some research has noted specific considerations for individuals with pre-existing heart conditions. These studies evaluated the risk profile in specific patient populations.
  • Renal Function: Monitoring of kidney function (e.g., serum creatinine) was included in many trials to track potential changes during treatment. Information suggests that researchers included monitoring of renal parameters in the study protocols.

Combination Therapy Research

Studies have evaluated the combination of this compound with other treatments commonly used in research protocols (e.g., Methotrexate) to investigate the overall outcome.

  • Reported magnitude of changes in symptoms was analyzed for the combination group versus monotherapy.
  • Onset of Action: Some studies have examined the onset of action to compare how quickly changes in reported symptoms were observed in the combination versus single-drug groups.
  • Flare-ups: Research evaluated changes in the recorded frequency of flare-ups when used as part of a combination regimen.

Key Studies & References

  1. Real-World Safety and Effectiveness of Rabeprazole–Domperidone Fixed-Dose Combination (Happi D) in Gastroesophageal Reflux Disease
  2. Expert opinion on the prescription practice of a combination of rabeprazole and domperidone for managing nighttime heartburn in GERD among Indian patients (Combination Therapy Analysis)

Frequently Asked Questions (FAQ)

Common questions about Rablet-D (FAQ)


Q: How quickly does Rablet-D start working after you take it?

A: According to the official product information, the medicine typically starts to show its effect within a few hours after consumption. Achieving the full prescribed therapeutic benefit may take a longer period, as determined by a healthcare professional.


Q: Are there any long-term side effects associated with taking Rablet-D?

A: Official warnings indicate that the long-term use (typically one year or more) of the Rabeprazole component may be associated with an increased risk for bone fractures related to osteoporosis. Regulatory documents also note a potential risk for Hypomagnesemia (low magnesium levels) and Vitamin B12 deficiency with prolonged use.


Q: Is it normal to feel a bit dizzy or nauseous when starting Rablet-D?

A: Yes, dizziness and nausea are both adverse drug reactions that have been reported in clinical data for this combination. They are typically classified as Common or Uncommon side effects. If these or other side effects persist or become bothersome, consulting a healthcare provider for guidance is advised.


Q: What are the signs of a serious allergic reaction to Rablet-D?

A: Signs of a serious allergic reaction may include swelling of the face, lips, tongue, or throat, or difficulty breathing and swallowing. Severe skin reactions, such as an itchy, lumpy rash (hives) are also possible, as noted in the official safety information. These symptoms require immediate medical evaluation.


Q: Does Rablet-D affect the absorption of vitamins or minerals?

A: Regulatory warnings mention that prolonged use (such as longer than three years) of the Rabeprazole component may lead to a Vitamin B12 deficiency. Additionally, low magnesium levels (Hypomagnesemia) have been reported rarely with extended treatment. Monitoring of these levels may be performed during long-term therapy.


Q: Is it okay to take Rablet-D if I have existing kidney problems?

A: The elimination of the Domperidone component can be prolonged in cases of severe kidney impairment. For this reason, official information states that for patients with severe renal issues who require repeated administration, the dosing frequency may need to be reduced. Consultation with a healthcare provider is necessary for patients with kidney issues before starting this combination.


Q: Are there any known issues with Rablet-D and heart conditions?

A: Yes, regulatory documents strictly state that Rablet-D must not be used in patients with pre-existing heart diseases, a history of QT interval prolongation, or significant electrolyte disturbances. This is due to the potential risk of serious heart rhythm abnormalities (ventricular arrhythmias) associated with the Domperidone component.


Q: Is Rablet-D linked to any risk of bone density loss?

A: Official warnings indicate that long-term therapy with the Rabeprazole component, particularly at high doses, may be associated with an increased risk for fractures of the hip, wrist, or spine. This risk is related to the possibility of bone density changes over time.


Q: What happens if I take too much Rablet-D by mistake?

A: Overdose can cause symptoms such as agitation, altered consciousness, convulsions, disorientation, or excessive sleepiness. Regulatory documents advise that immediate medical assistance should be sought if an overdose is suspected.


Q: Can Rablet-D help with bloating or gas?

A: The Domperidone component of Rablet-D is a prokinetic agent, meaning it works to enhance gastric emptying (the movement of food out of the stomach). This action may help relieve the symptoms of bloating or a feeling of fullness that is associated with delayed stomach motility.


Q: Why do some people say Rablet-D helps with their stomach pain?

A: Rablet-D is officially indicated for the treatment of conditions like stomach ulcers and GERD, both of which cause significant stomach pain. The Rabeprazole component reduces the acid that causes irritation, while the Domperidone component improves movement, which together can relieve this discomfort.


Q: Is it safe to stop taking Rablet-D suddenly?

A: Official guidance advises that discontinuation of this combination should occur only after consulting a healthcare professional. This is important to ensure the underlying condition remains controlled and to avoid any potential symptoms that may occur upon abrupt cessation.


Q: Can I drive or operate machinery after taking Rablet-D?

A: Official warnings state that this combination medicine may affect a person's ability to drive or operate heavy machinery. If dizziness or sleepiness (reported side effects) occur after taking the medicine, avoiding driving or operating machinery is recommended.


Q: Does Rablet-D affect sleep?

A: Sleepiness (somnolence) is listed in regulatory documents as an Uncommon adverse drug reaction for this combination. If unusual changes to sleep patterns or excessive drowsiness are experienced, consultation with a doctor is appropriate.


Q: What is the shelf life of Rablet-D tablets?

A: While the specific shelf life can vary by manufacturer and packaging, the industry standard for this type of capsule formulation is typically 24 months from the date of manufacture. It should be stored in the original container at room temperature and protected from moisture and light.


Q: Why might a doctor prescribe Rablet-D instead of a standalone PPI?

A: The combination is designed to provide a dual-action therapeutic approach. A doctor may prescribe it when a patient requires both the strong acid suppression of the Rabeprazole component and the motility-enhancing effects of the Domperidone component to address both chemical and physical digestive issues.


Q: Does Rablet-D affect the results of any common medical tests?

A: Official warnings note that the Rabeprazole component may cause an increase in serum chromogranin A ( CgA) levels. This can potentially interfere with the diagnostic investigations for neuroendocrine tumors.


Q: What should I do if the Rablet-D seems like it's not working anymore?

A: If a patient experiences a suboptimal response or an early relapse of symptoms, regulatory documents state that the doctor should consider additional follow-up and diagnostic testing. Symptomatic relief does not rule out the possibility of an underlying gastric malignancy, so consulting a doctor is important for further evaluation.


Q: Can Rablet-D be taken with common pain relievers like ibuprofen?

A: While no specific drug interaction is reported between the combination and Nonsteroidal Anti-inflammatory Drugs ( NSAIDs) like ibuprofen, NSAIDs can cause or worsen gastrointestinal side effects. As the medicine is often used to treat or prevent these effects, any co-administration requires discussion with a healthcare provider.


Q: How is Rablet-D different from a simple antacid?

A: Rablet-D is fundamentally different because it is a dual-action prescription medicine. Unlike simple antacids that only neutralize existing stomach acid, Rablet-D blocks acid production (Rabeprazole) and enhances the physical movement of the digestive tract (Domperidone).


Q: Can taking Rablet-D make your mouth dry?

A: Yes, dry mouth is a side effect that is listed in the regulatory safety documents for this combination medicine.


Q: Why do some people use Rablet-D for indigestion?

A: Rablet-D is officially indicated for the treatment of various conditions including functional dyspepsia, which is a common form of indigestion. It targets related symptoms such as heartburn, nausea, and a feeling of fullness.


Q: How does the Domperidone component work in the stomach?

A: The Domperidone component works by blocking specific dopamine receptors in the upper part of the digestive tract. This action enhances the natural motility, or movement, of the stomach, helping to increase the rate of stomach emptying and strengthen the lower esophageal sphincter.


Q: Can Rablet-D be used for a short period, like just a few days?

A: For the Domperidone component, regulatory guidance often stresses using it for the shortest possible duration, generally not exceeding one week, due to heart rhythm risks. The overall course length for the combination should be determined by a healthcare professional based on the specific condition being treated.


Q: Can Rablet-D be used for conditions other than acid reflux?

A: Yes, regulatory documents indicate that this combination is also used in the treatment of stomach ulcers and a condition known as Zollinger-Ellison syndrome, where the stomach produces an excessive amount of acid.

How should Rablet-D be stored and disposed of?

Storage and Disposal Instructions for Rablet-D

Rablet-D (Rabeprazole Sodium and Domperidone) must be stored and handled in accordance with official labeling to maintain product stability and integrity.

Storage Requirement Official Condition
Temperature Store at room temperature; keep from freezing and excessive heat.
Protection Keep in a cool, dry place, protected from moisture and direct light.
Container Store in the original container and keep the lid tightly closed.

Child Safety: The medicine must be kept out of the reach and sight of children to prevent accidental ingestion.

Disposal: Do not keep outdated or unused medicine. Patients must ask a healthcare professional or follow regulatory guidance for discarding the product, which includes making the product unappealing before disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rablet-D found in:

A-Z Index: